U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H21NO7
Molecular Weight 267.2762
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VOGLIBOSE

SMILES

OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O

InChI

InChIKey=FZNCGRZWXLXZSZ-CIQUZCHMSA-N
InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1

HIDE SMILES / InChI

Description

Voglibose is an alpha glucosidase inhibitor, which was initially marketed in Japan as an improving agent for postprandial hyperglycemia in diabetes mellitus. Later on the drug was approved for the prevention of type 2 diabetes. The drug is available in Asia under the name Basen.

Originator

Approval Year

Unknown
134361
Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: alpha-Glucosidase
Inhibitor
8228
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8360
BASEN

Approved Use

Improvement of postprandial hyperglycemia in diabetes mellitus

Launch Date

7.7302078E11
Preventing
Approved
8360
BASEN

Approved Use

Prevention of the onset of type 2 diabetes in patients with impaired glucose tolerance.

Launch Date

1.25591041E12
PubMed

PubMed

TitleDatePubMed
Synthesis and glycosidase inhibitory activity of new hexa-substituted C8-glycomimetics.
2005 Oct 7
Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study.
2006 Apr
Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice.
2006 Apr 1
A rare case of adult-onset nesidioblastosis treated successfully with diazoxide.
2006 Feb
An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients.
2006 Jun
Voglibose inhibits postprandial hypotension in neurologic disorders and elderly people.
2006 May 9
Abnormal glucose tolerance contributes to the progression of chronic heart failure in patients with dilated cardiomyopathy.
2006 Oct
Quantitative determination of voglibose in pharmaceutical tablets using high-performance liquid chromatography-fluorescence detection with post-column derivatization and mass spectrometric detection.
2006 Sep 26
A review of nateglinide in the management of patients with type 2 diabetes.
2007
Determination of miglitol in human plasma by liquid chromatography/tandem mass spectrometry.
2007
Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers.
2007 Apr
Indian herbs and herbal drugs used for the treatment of diabetes.
2007 May
Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice.
2007 May
Thioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetes.
2007 May 5
Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis.
2007 Nov
Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients.
2007 Oct
[Adverse effects of alpha-glucosidase inhibitors].
2007 Oct 28
Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes.
2007 Sep
Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes.
2008
Peroxisome proliferator-activated receptors in diabetic nephropathy.
2008
Protective Actions of PPAR-gamma Activation in Renal Endothelium.
2008
Change in long-spacing collagen in Descemet's membrane of diabetic Goto-Kakizaki rats and its suppression by antidiabetic agents.
2008
PPAR Agonists and Cardiovascular Disease in Diabetes.
2008
Alpha-glucosidase-like activity detected in a siboglinid polychaete, Oligobrachia mashikoi.
2008 Apr
Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients.
2008 Aug
Acute progression of severe insulin edema accompanied by pericardial and pleural effusion in a patient with type 2 diabetes.
2008 Aug
Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetes.
2008 Dec
Effects of antidiabetic drugs on glucose tolerance in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic mice.
2008 Dec
Hypoglycaemic effects of antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic rats.
2008 Dec
Involvement of hyperglycemia in deposition of aggregated protein in glomeruli of diabetic mice.
2008 Dec 28
Improvement in medication compliance and glycemic control with voglibose oral disintegrating tablet.
2008 Nov
Pneumatosis cystoides intestinalis following alpha-glucosidase inhibitor treatment: a case report and review of the literature.
2008 Oct 21
Intramolecular direct aldol reactions of sugar diketones: syntheses of valiolamine and validoxylamine G.
2008 Sep 18
Design and synthesis of 5a-carbaglycopyranosylamime glycosidase inhibitors.
2009
Alpha-glucosidase inhibition assay in an enzyme-immobilized amino-microplate.
2009 Apr
Voglibose for prevention of type 2 diabetes mellitus.
2009 Aug 8
Topics in type 2 diabetes and insulin resistance.
2009 Feb
Comparison of pre- versus post-meal administration of voglibose in men with or without impaired glucose tolerance.
2009 Feb
Genetically engineered production of 1,1'-bis-valienamine and validienamycin in Streptomyces hygroscopicus and their conversion to valienamine.
2009 Jan
Suppressive response of confections containing the extractive from leaves of Morus Alba on postprandial blood glucose and insulin in healthy human subjects.
2009 Jul 14
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.
2009 Jul 20
Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
2009 Jun
[Simultaneous determination of four highly polar anti-diabetic drugs in Chinese traditional patent medicines using high performance liquid chromatography].
2009 Mar
Novel LMNA gene mutation in a patient with Atypical Werner's Syndrome.
2009 Mar
Effects of the combination of dipeptidyl peptidase-IV inhibitor ASP8497 and antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic mice.
2009 Mar 1
Development and validation of LC methods with visible detection using pre-column derivatization and mass detection for the assay of voglibose.
2009 Mar 15
Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
2009 May
Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.
2009 May 1
Voglibose for prevention of type 2 diabetes mellitus.
2009 May 9
Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.
2009 May 9
Patents

Patents

JP2000103731A
7
JP2000344660A
1
JP2000504736A
1
JP2000505784A
1
JP2000507197A
1
JP2000515113A
1
JP2001002567A
1
JP2001509795A
2
JP2001515084A
1
JP2001523704A
2
JP2002500643A
10
JP2002520418A
1
JP2002537393A
1
JP2002542232A
1
JP2002542344A
1
JP2003500078A
1
JP2003500474A
1
JP2003500475A
1
JP2003505358A
1
JP2003506426A
1
JP2003509401A
1
JP2003510350A
1
JP2003511451A
1
JP2003517303A
1
JP2003517466A
1
JP2003522758A
4
JP2004315496A
25
JP2004502792A
1
JP2004525900A
3
JP2004527465A
1
JP2004536830A
1
JP2005502735A
1
JP2005511566A
1
JP2005511570A
1
JP2005511694A
1
JP2005512806A
1
JP2005516018A
1
JP2005522496A
1
JP2005522510A
1
JP2005522511A
1
JP2005526795A
3
JP2005535584A
1
JP2005535649A
1
JP2005538073A
1
JP2005538968A
1
JP2006008548A
1
JP2006016388A
1
JP2006131564A
1
JP2006501063A
1
JP2006502119A
1
JP2006503013A
1

Sample Use Guides

In Vivo Use Guide
Tablets are orally administered in a single dose of 0.2 mg as voglibose, three times a day, just before each meal.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
VOGLIBOSE
INN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
VOGLIBOSE [USAN]
Common Name English
Voglibose [WHO-DD]
Common Name English
D-EPI-INOSITOL, 3,4-DIDEOXY-4-((2-HYDROXY-1-(HYDROXYMETHYL)ETHYL)AMINO)-2-C-(HYDROXYMETHYL)-
Systematic Name English
BASEN
Brand Name English
VOGLIBOSE [JAN]
Common Name English
AO-128
Code English
A-71100
Code English
3,4-DIDEOXY-4-((2-HYDROXY-1-(HYDROXYMETHYL)ETHYL)AMINO)-2-C-(HYDROXYMETHYL)-D-EPI-INOSITOL
Systematic Name English
N-(1,3-DIHYDROXY-2-PROPYL)VALIOLAMINE
Common Name English
VOGLIBOSE [MI]
Common Name English
voglibose [INN]
Common Name English
VOGLIBOSE [MART.]
Common Name English
Classification Tree Code System Code
WHO-ATC A10BF03
Created by admin on Thu Jul 06 23:10:00 UTC 2023 , Edited by admin on Thu Jul 06 23:10:00 UTC 2023
NCI_THESAURUS C2846
Created by admin on Thu Jul 06 23:10:00 UTC 2023 , Edited by admin on Thu Jul 06 23:10:00 UTC 2023
WHO-VATC QA10BF03
Created by admin on Thu Jul 06 23:10:00 UTC 2023 , Edited by admin on Thu Jul 06 23:10:00 UTC 2023
NCI_THESAURUS C29711
Created by admin on Thu Jul 06 23:10:00 UTC 2023 , Edited by admin on Thu Jul 06 23:10:00 UTC 2023
Code System Code Type Description
SMS_ID
100000079326
Created by admin on Thu Jul 06 23:10:00 UTC 2023 , Edited by admin on Thu Jul 06 23:10:00 UTC 2023
PRIMARY
DRUG CENTRAL
2845
Created by admin on Thu Jul 06 23:10:00 UTC 2023 , Edited by admin on Thu Jul 06 23:10:00 UTC 2023
PRIMARY
CAS
83480-29-9
Created by admin on Thu Jul 06 23:10:00 UTC 2023 , Edited by admin on Thu Jul 06 23:10:00 UTC 2023
PRIMARY
ChEMBL
CHEMBL476960
Created by admin on Thu Jul 06 23:10:00 UTC 2023 , Edited by admin on Thu Jul 06 23:10:00 UTC 2023
PRIMARY
EVMPD
SUB00085MIG
Created by admin on Thu Jul 06 23:10:00 UTC 2023 , Edited by admin on Thu Jul 06 23:10:00 UTC 2023
PRIMARY
DRUG BANK
DB04878
Created by admin on Thu Jul 06 23:10:00 UTC 2023 , Edited by admin on Thu Jul 06 23:10:00 UTC 2023
PRIMARY
MESH
C102817
Created by admin on Thu Jul 06 23:10:00 UTC 2023 , Edited by admin on Thu Jul 06 23:10:00 UTC 2023
PRIMARY
CHEBI
22695
Created by admin on Thu Jul 06 23:10:00 UTC 2023 , Edited by admin on Thu Jul 06 23:10:00 UTC 2023
PRIMARY
INN
6797
Created by admin on Thu Jul 06 23:10:00 UTC 2023 , Edited by admin on Thu Jul 06 23:10:00 UTC 2023
PRIMARY
FDA UNII
S77P977AG8
Created by admin on Thu Jul 06 23:10:00 UTC 2023 , Edited by admin on Thu Jul 06 23:10:00 UTC 2023
PRIMARY
WIKIPEDIA
Voglibose
Created by admin on Thu Jul 06 23:10:00 UTC 2023 , Edited by admin on Thu Jul 06 23:10:00 UTC 2023
PRIMARY
EPA CompTox
DTXSID2021442
Created by admin on Thu Jul 06 23:10:00 UTC 2023 , Edited by admin on Thu Jul 06 23:10:00 UTC 2023
PRIMARY
MERCK INDEX
M11496
Created by admin on Thu Jul 06 23:10:00 UTC 2023 , Edited by admin on Thu Jul 06 23:10:00 UTC 2023
PRIMARY Merck Index
PUBCHEM
444020
Created by admin on Thu Jul 06 23:10:00 UTC 2023 , Edited by admin on Thu Jul 06 23:10:00 UTC 2023
PRIMARY
USAN
KK-13
Created by admin on Thu Jul 06 23:10:00 UTC 2023 , Edited by admin on Thu Jul 06 23:10:00 UTC 2023
PRIMARY
NCI_THESAURUS
C95221
Created by admin on Thu Jul 06 23:10:00 UTC 2023 , Edited by admin on Thu Jul 06 23:10:00 UTC 2023
PRIMARY
ACTIVE MOIETY
Structure of VOGLIBOSE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966